FDA Considers Withdrawing Amgen's Rare Disease Drug

• FDA cited lack of proven effectiveness and untrue statements in Amgen's application as reasons for the proposed withdrawal
• In March 2025, FDA identified cases of drug-induced liver injury with a causal link to Tavneos, including seven cases of vanishing bile duct syndrome (VBDS), a rare condition causing permanent liver damage
• Eight deaths were reported among the liver injury cases associated with the drug

Summary

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research has proposed withdrawing approval for Amgen's Tavneos, a treatment for rare autoimmune diseases. The agency cited two primary concerns: lack of proven effectiveness and untrue statements in the original approval application.

Key Safety Issues:

In March, the FDA identified serious cases of drug-induced liver injury linked to Tavneos, including seven cases of vanishing bile duct syndrome (VBDS)—a rare condition that can cause permanent liver damage. Among these cases, eight deaths were reported, raising significant safety concerns about the medication.

Market Implications:

This proposed withdrawal represents a major setback for Amgen, as it affects a rare disease drug that underwent the approval process with apparently insufficient or inaccurate data. The action highlights increased FDA scrutiny on both drug efficacy and the integrity of approval applications. The safety signals, particularly the fatalities associated with liver complications, suggest potential liability concerns for the company.

The dual rationale for withdrawal—both efficacy failures and fraudulent application statements—is particularly damaging and could trigger further regulatory reviews of Amgen's other products or pending applications. This development may impact investor confidence in Amgen's pipeline integrity and regulatory compliance processes.

For the broader pharmaceutical sector, this serves as a cautionary example of heightened regulatory oversight, especially for rare disease treatments where clinical trial standards and post-market surveillance are critical. Investors should monitor Amgen's response and any potential financial impact from the drug's withdrawal, including possible legal ramifications from the alleged false statements in the approval application.